# EDGAR Filing Document

**Accession Number:** 0001437151
**File Stem:** 0001209191-23-014818
**Filing Date:** 2023-3
**Character Count:** 12731
**Document Hash:** f08ef6358cd6f176c7d4b6dd35982325
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-014818.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001209191-23-014818

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230228

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** HAJOST MICHAEL A
- **CENTRAL INDEX KEY:** 0001437151

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39280
- **FILM NUMBER:** 23700252

**MAIL ADDRESS:**
- **STREET 1:** C/O CARPENTER TECHNOLOGY CORPORATION
- **STREET 2:** PO BOX 14662
- **CITY:** READING
- **STATE:** PA
- **ZIP:** 19612-4662
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Danimer Scientific, Inc.
- **CENTRAL INDEX KEY:** 0001779020
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **IRS NUMBER:** 841924518
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 140 INDUSTRIAL BOULEVARD
- **CITY:** BAINBRIDGE
- **STATE:** GA
- **ZIP:** 39817
- **BUSINESS PHONE:** 229-243-7075

**MAIL ADDRESS:**
- **STREET 1:** 140 INDUSTRIAL BOULEVARD
- **CITY:** BAINBRIDGE
- **STATE:** GA
- **ZIP:** 39817

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Danimer Scientific, Inc
- **DATE OF NAME CHANGE:** 20201229

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Live Oak Acquisition Corp
- **DATE OF NAME CHANGE:** 20200106

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Foxhound Merger Partners, Inc.
- **DATE OF NAME CHANGE:** 20190605

## Ex-24

```
<PRE>
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

	Know all by these presents, that the undersigned's hereby makes, constitutes
and appoints Stephen A. Martin, Spencer E. Walker, Michael S. Nancarrow, and
Blake R. Chamblee as the undersigned's true and lawful attorney-in-fact, with
full power and authority as hereinafter described on behalf of and in the name,
place and stead of the undersigned to:

(1)	prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including
any amendments thereto) with respect to the securities of Danimer Scientific,
Inc., a Delaware corporation (the "Company"), with the United States Securities
and Exchange Commission, any national securities exchanges and the Company, as
considered necessary or advisable under Section 16(a) of the Securities Exchange
Act of 1934 and the rules and regulations promulgated thereunder, as amended
from time to time (the "Exchange Act");

(2)	seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information on transactions in the Company's securities from any third
party, including brokers, employee benefit plan administrators and trustees, and
the undersigned hereby authorizes any such person to release any such
information to the undersigned and approves and ratifies any such release of
information; and

(3)	perform any and all other acts which in the discretion of such
attorney-in-fact are necessary or desirable for and on behalf of the undersigned
in connection with the foregoing.

The undersigned acknowledges that:

(1)	this Power of Attorney authorizes, but does not require, such
attorney-in-fact to act in their discretion on information provided to such
attorney-in-fact without independent verification of such information;

(2)	any documents prepared and/or executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney will be in such form and will
contain such information and disclosure as such attorney-in-fact, in his or her
discretion, deems necessary or desirable;

(3)	neither the Company nor such attorney-in-fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such
requirements, or (iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and

(4)	this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.

	The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Limited Power of Attorney.

	This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to such attorney-in-fact.
	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 23rd day of January, 2023.

                              ___/s/ Michael A. Hajost______________
                                         Signature

                              ___Michael A. Hajost__________________
                                         Print Name

STATE OF GEORGIA
COUNTY OF DECATUR

	On this 23rd day of January, 2023, Michael A. Hajost personally appeared before
me, and acknowledged that s/he executed the foregoing instrument for the
purposes therein contained.

	IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

                                  ___Darla Ann Castoro_________________
                                         Notary Public

                                   ___/s/ Darla Ann Castoro____________
                    							____3/8/2025_______________________
                                         My Commission Expires:

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>HAJOST MICHAEL A<br><sub>(Last) (First) (Middle)</sub><br>C/O DANIMER SCIENTIFIC, INC.<br>140 INDUSTRIAL BOULEVARD<br><sub>(Street)</sub><br>BAINBRIDGE, GA 39817<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Danimer Scientific, Inc. [ DNMR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $2.58 | 2023-02-28 |  | A |  | 149254 |  | <sup>(1)</sup> | 2033-02-28 | Common Stock | 149254 | $0.00 | 149254 | D |  |
| Performance Stock Award | $0.00 | 2023-02-28 |  | A |  | 77519 |  | <sup>(2)(3)(4)</sup> | <sup>(5)</sup> | Common Stock | 77519 | $0.00 | 77519 | D |  |

---

### Footnotes:

(1) The option to purchase shares of the Issuer's Class A common stock ("Common Stock") was granted to Reporting Person on February 28, 2023 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). Options to purchase 49,751 shares of the Issuer's Common Stock will vest and become exercisable on each of February 28, 2024, February 28, 2025 and 49,752 shares of the Issuer's Common Stock will vest and become exercisable on February 28, 2026.

(2) Comprised of a performance stock award (the "PSA") granted under the Plan consisting of 77,519 performance shares of the Common Stock (the "Performance Shares").

(3) Under the PSA, the Performance Shares will be issued only if  they have vested in accordance with the following vesting criteria:
(i) 50% of the Performance Shares (the "Total PHA Revenue Metric Shares") will be subject to vesting upon achievement of the Total PHA Revenue metric as follows: the threshold for vesting of the Total PHA Revenue Metric Shares will be the Issuer achieving Total PHA Revenue of at least $177 million, in which event 50% of the Total PHA Revenue Metric Shares will vest, and upon the Issuer achieving Total PHA Revenue of $202 million, 100% of the Total PHA Revenue Metric Shares will vest, with pro rata vesting of the Total PHA Revenue Metric Shares for any amount of Total PHA Revenue in between such ranges (in each case without duplication);

(4) (ii) 50% of the Performance Shares (the "Adjusted EBITDA Metric Shares") will be subject to vesting upon achievement of the earnings before interest, taxes, depreciation and amortization, including all adjustments made for reporting this metric in public filings ("Adjusted EBITDA") as follows: the threshold for vesting the Adjusted EBITDA Metric Shares will be the Issuer achieving Adjusted EBITDA of at least $36 million, in which event 50% of the Adjusted EBITDA Metric Shares will vest, and upon the Issuer achieving $44 million of Adjusted EBITDA, 100% of the Adjusted EBITDA Metric Shares will vest, with pro rata vesting of the Adjusted EBITDA Metric Shares for any amount of Adjusted EBITDA in between such ranges (in each case without duplication).

(5) The earlier of February 28, 2026 or the Reporting Person's Termination Date (as defined in the Plan).

**Signature:** /s/Stephen A. Martin, attorney-in-fact  
**Date:** 2023-03-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**